Vir Biotechnology will present two-year efficacy and safety data for tobevibart combined with elebsiran in chronic hepatitis delta, a condition with no approved U.S. treatments. The trial includes analysis of how metabolic factors influence viral control and treatment response.
Key Points
- Two-year data on combination monoclonal antibody and siRNA therapy
- Subgroup analysis examines body mass index impact on viral response
- No approved hepatitis delta treatments currently available in U.S.
Longevity Analysis
Chronic hepatitis delta accelerates liver fibrosis and cirrhosis progression, substantially reducing lifespan and healthspan through sustained viral replication and immune dysregulation. A combination approach targeting multiple pathways—surface antigen neutralization and hepatitis B surface antigen reduction—addresses the cascade of hepatic dysfunction rather than isolated symptoms. The investigation of metabolic factors (body mass index) alongside viral control reflects recognition that metabolic state modulates both immune response capacity and liver regeneration potential, two mechanisms central to recovery from chronic viral challenge. Treatment success in this population would remove a significant barrier to hepatic restoration and reduce the chronic inflammatory burden that accelerates age-related diseases.
Original published by LT Wire.